{"entity":{"id":"scott-plotkin","kind":"person","name":"Scott R. Plotkin","aka":[],"tldr":"Boston neuro-oncologist who showed that bevacizumab can shrink vestibular schwannomas and restore hearing in people with neurofibromatosis type 2.","summary":"Scott Plotkin is a neuro-oncologist at Massachusetts General Hospital who directs its neurofibromatosis centre. He was first author of the 2009 New England Journal of Medicine report showing that the VEGF antibody bevacizumab reduced tumour volume and improved hearing in patients with neurofibromatosis type 2 and progressive vestibular schwannomas, the first medical therapy for these tumours. He leads the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) collaboration.","asOf":"2026-09-18","links":[],"tags":["brain","rare-cancers","trialist"],"related":[],"cancers":["vestibular-schwannoma","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mgh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-plotkin-bevacizumab-nf2-nejm-2009"],"journals":[],"dependsOn":[],"notes":[],"role":"Neuro-oncologist and Director of the Family Center for Neurofibromatosis, Massachusetts General Hospital","institutionId":"mgh","specialisms":["Neurofibromatosis type 2","Schwannomas","Neuro-oncology trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Plotkin%5BAuthor%5D"}],"papers":[],"orcid":"0000-0002-6109-6419"},"route":"/people/scott-plotkin/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"vestibular-schwannoma","kind":"cancer","name":"Vestibular schwannoma (acoustic neuroma)","route":"/cancers/vestibular-schwannoma/"}],"institution":[{"id":"mgh","kind":"institution","name":"Massachusetts General Hospital Cancer Center","route":"/institutions/mgh/"}],"paper":[{"id":"paper-plotkin-bevacizumab-nf2-nejm-2009","kind":"paper","name":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","route":"/key-papers/paper-plotkin-bevacizumab-nf2-nejm-2009/"}]}}